Q1 2026

Filed May 8, 2026 · 10-Q · 38 days after period end · 0001372514-26-000047

Q1 2026 · 10-Q

Revenue—

Net Income

-$2.42M

N/M vs Q1 2025

EPS Diluted

-$0.58

N/M vs Q1 2025

Operating Income-$2,510,195N/M

Operating Cash Flow-$3,161,332N/M

Same quarter

Metric	Q1 2026	Q1 2025	Q1 2024	Q1 2023
Revenue	—	$0.00	$16.00M	$0.00
Net Income	-$2.42M	-$2.19M	$13.45M	-$1.87M
EPS Diluted	-$0.58	-$0.52	$3.46	-$1.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Kiora Pharmaceuticals Inc · CIK 1372514 · Engraved from SEC EDGAR